December 2, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

Arcutis reports Q3 loss, but first product revenue

IN THIS ARTICLE

Westlake Village-based Arcutis’ losses continue to mount, but in the third quarter of 2022 it recorded product revenue for the first time in its history. Arcutis, a biotechnology company focused on treating skin diseases, launched its first product, Zoryve, in August. Zoryve is a cream focused on the treatment of plaque psoriasis in adolescents and…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.

Leave a Reply

Your email address will not be published.